Agenus Inc. reported third-quarter 2026 total revenue of $31.5 million and an operating income of $11.4 million, marking the third consecutive quarter of profitability. The company holds $86.9 million in cash, cash equivalents, and short-term investments. Armenia granted the first worldwide marketing authorizations for botensilimab and balstilimab for metastatic colorectal cancer. Agenus Inc. is an immuno-oncology company developing immunological agents to treat cancer.
